Pertussis Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis

The Pertussis Vaccine Market is valued at USD 6.9 billion in 2025 and is projected to grow at a CAGR of 5% to reach USD 10.7 billion by 2034.

Pertussis Vaccine Market Overview

The pertussis vaccine market is a crucial segment within the global immunization market, driven by the ongoing need to prevent whooping cough, a contagious and potentially severe respiratory illness. Pertussis, caused by the bacterium *Bordetella pertussis*, is highly contagious and can lead to serious health complications, particularly in infants, young children, and the elderly. Vaccination remains the most effective means of controlling the spread of pertussis, with both children and adults being recommended to receive the vaccine. The global pertussis vaccine market includes a range of vaccines, such as the DTP (diphtheria, tetanus, pertussis) combination vaccine and other formulations tailored for infants, adolescents, and adults. With the continued incidence of pertussis cases worldwide, especially in areas with low vaccination coverage, the market for pertussis vaccines remains essential to public health. Efforts to improve vaccination rates, alongside advancements in vaccine formulations and delivery systems, are driving the growth of the market. Governments, healthcare organizations, and NGOs play key roles in funding and promoting immunization programs, particularly in low- and middle-income countries, where pertussis remains a major health threat.

The pertussis vaccine market has seen several key developments aimed at improving vaccine efficacy and accessibility. Advances in vaccine formulations have focused on enhancing the safety and effectiveness of pertussis vaccines, with newer versions offering fewer side effects and improved protection. There has been an increased emphasis on the development of combination vaccines, which not only protect against pertussis but also provide immunization for other diseases, such as diphtheria, tetanus, and polio. The use of acellular pertussis vaccines, which contain purified components of the *Bordetella pertussis* bacteria rather than the whole cell, continues to dominate in many regions due to their better safety profile. In addition, booster shots for adolescents and adults have become a major focus in many countries to maintain immunity, particularly given the resurgence of pertussis cases in some areas. Governments and health organizations are also prioritizing vaccination campaigns and outreach programs to boost vaccination coverage in underserved populations. Furthermore, the rise of mobile health technologies and digital platforms has allowed for more efficient tracking of vaccination schedules and delivery, ensuring that vaccines reach those in need more effectively.

The pertussis vaccine market is expected to continue growing, driven by further advancements in vaccine technology, increased vaccination awareness, and the ongoing efforts to eliminate the disease globally. As the world moves towards achieving higher immunization coverage, there is expected to be more investment in research to develop next-generation vaccines with longer-lasting protection and fewer side effects. Additionally, there is potential for increased focus on maternal immunization, as vaccinating pregnant women can help protect newborns from pertussis during the first few months of life. With continued global health initiatives and stronger emphasis on immunization in low-income countries, access to pertussis vaccines will improve, particularly in regions where the disease burden is highest. Further advancements in vaccine delivery systems, such as needle-free injections or improved vaccine storage solutions, could increase vaccine availability and reduce logistical challenges, helping to reach remote or hard-to-reach populations. The future of the pertussis vaccine market is promising, with global efforts to eradicate the disease and ensure widespread access to life-saving vaccines continuing to drive market growth.

Key Insights: Pertussis Vaccine Market

• Advancements in Vaccine Formulations: Continuous improvements in acellular pertussis vaccines offer better safety profiles, enhanced protection, and fewer side effects.
• Combination Vaccines Gaining Popularity: Combination vaccines that protect against multiple diseases, such as DTP vaccines, are becoming more common, improving vaccine coverage and reducing the need for multiple injections.
• Maternal Immunization Focus: Increasing emphasis on vaccinating pregnant women to protect newborns from pertussis during the early months of life is becoming a significant trend in immunization strategies.
• Adolescent and Adult Boosters: More countries are introducing booster doses for adolescents and adults to maintain immunity levels and reduce pertussis incidence in older populations.
• Digital Platforms for Vaccine Tracking: The use of mobile health apps and digital platforms is growing, enabling better tracking of vaccination schedules and increasing vaccine delivery efficiency.
• Increased Awareness of Pertussis Resurgence: Rising awareness about the resurgence of pertussis cases, particularly in unvaccinated populations, is driving demand for the pertussis vaccine.
• Government and Global Health Initiatives: Global immunization campaigns, particularly in low-income countries, are prioritizing pertussis vaccination as a key part of public health efforts.
• Technological Advancements in Vaccine Production: Continuous advancements in vaccine production and storage technologies make it easier to produce and distribute vaccines globally, improving access to immunization.
• Focus on Maternal and Adolescent Immunization: Growing emphasis on maternal and adolescent vaccination programs, especially in high-risk populations, is expanding vaccine coverage and preventing the spread of pertussis.
• Vaccine Accessibility in Low-Income Regions: Ensuring consistent access to pertussis vaccines in underserved and remote regions, where vaccine coverage is still low, remains a significant challenge for global health organizations.

Pertussis Vaccine Market Segmentation

By Product Type

• DTaP (Diphtheria
• Tetanus and Acellular Pertussis) Vaccine
• Tdap (Tetanus
• Diphtheria and Pertussis) Vaccine

By Vaccine Type

• Whole-Cell Vaccine
• Acellular Vaccine

By Application

• Children
• Adults
• Infants

By End-User

• Vaccination Centers
• Hospitals
• Clinics

Key Companies Analysed

• Pfizer Inc.
• Johnson and Johnson Pvt Ltd.
• Merck and Co. Inc.
• Novartis AG
• GlaxoSmithKline PLC
• AstraZeneca PLC
• BioNTech SE
• Moderna Inc.
• Sinovac Biotech Ltd.
• CSL Limited
• Astellas Pharma US Inc.
• Sanofi Pasteur SA
• Mitsubishi Tanabe Pharma America Inc.
• PT Kalbe Farma Tbk
• CSL Seqirus
• Walvax Biotechnology Co.Ltd.
• Biological E. Limited
• Serum Institute of India
• Bavarian Nordic AS
• PT Bio Farma
• Bharat Biotech International Limited
• Takeda Pharmaceutical Company
• Panacea Biotec Limited
• Beijing Minhai Biotechnology Co. Ltd.
• Protein Sciences Corporation
• Wuhan Institute of Biological Products
• Changchun Changsheng Life Sciences
• Changsheng Bio-Technology Co. Ltd.
• Gennova Biopharmaceuticals Ltd.
• Chiron Corporation.

Pertussis Vaccine Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modeling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Pertussis Vaccine Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

• North America - Pertussis Vaccine market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Pertussis Vaccine market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • BeNeLux
  • Russia
  • Sweden
  
  
• Asia-Pacific - Pertussis Vaccine market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Pertussis Vaccine market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Pertussis Vaccine market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru

Research Methodology

This study combines primary inputs from industry experts across the Pertussis Vaccine value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

• What is the current and forecast market size of the Pertussis Vaccine industry at global, regional, and country levels?
• Which types, applications, and technologies present the highest growth potential?
• How are supply chains adapting to geopolitical and economic shocks?
• What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?
• Who are the leading players, and how are their strategies evolving in the face of global uncertainty?
• Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?
• Where are the most investable opportunities - across technology roadmaps, sustainability-linked innovation, and M&A - and what is the best segment to invest over the next 3-5 years?

Your Key Takeaways from the Pertussis Vaccine Market Report

• Global Pertussis Vaccine market size and growth projections (CAGR), 2024-2034
• Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Pertussis Vaccine trade, costs, and supply chains
• Pertussis Vaccine market size, share, and outlook across 5 regions and 27 countries, 2023-2034
• Pertussis Vaccine market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
• Short- and long-term Pertussis Vaccine market trends, drivers, restraints, and opportunities
• Porter’s Five Forces analysis, technological developments, and Pertussis Vaccine supply chain analysis
• Pertussis Vaccine trade analysis, Pertussis Vaccine market price analysis, and Pertussis Vaccine supply/demand dynamics
• Profiles of 5 leading companies - overview, key strategies, financials, and products
• Latest Pertussis Vaccine market news and developments

Additional Support

With the purchase of this report, you will receive:

• An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
• Complimentary report update to incorporate the latest available data and the impact of recent market developments.

This product will be delivered within 1-3 business days.